Phase 2 Chronic Kidney Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form.
• People who have been diagnosed with chronic kidney disease, with kidney function test results showing an eGFR between 25 and 60 (a measure of how well the kidneys filter blood), and a urine protein level (UACR) of 300mg/g or higher at the screening visit.
• People who have been on a stable blood pressure medication routine for at least 2 weeks before the study begins, and who are able to stay on that routine throughout the study.
• People whose blood pressure reading at the screening visit is above 110/60 mmHg and below 150/90 mmHg (a short extended screening period may be allowed if blood pressure is slightly above this range, confirm with trial site).
• People who are able to understand and sign the consent form agreeing to take part.
• Women who could become pregnant may be considered, provided a pregnancy test at the screening visit comes back negative and a reliable form of contraception is used throughout the study.

Who may not be able to join:

• People currently taking amiloride (alone or combined with other medicines), or other potassium-sparing water tablets, or medicines that block mineralocorticoid receptors (such as spironolactone, eplerenone, or finerenone).
• People currently undergoing treatment for cancer.
• People who have received immune-suppressing medication within the 6 months before screening.
• People who have had an organ transplant at any point.
• People showing signs of an active infection (based on blood test results and a temperature above 38°C).
• People whose kidney disease has been unstable or declining rapidly in the 2 months before screening.
• People with severe liver disease classified as Child-Pugh grade C (a specific medical severity rating — confirm with trial site).
• People being treated for high blood pressure who have not been on a stable medication routine for at least 2 weeks before the study drug starts.
• People who are pregnant or breastfeeding.
• People with severe heart failure classified as NYHA Class IV, or who have unstable or acute heart failure (confirm with trial site).
• People who have had a heart procedure to open blocked arteries less than 2 months ago, a stroke or mini-stroke (TIA) within the past 2 months, or an acute heart attack event within the past 2 months.
• People whom the treating doctor considers to be at risk of becoming dehydrated.
• People with a known allergy or sensitivity to the study treatment or its ingredients.
• People with a known allergy or sensitivity to a medication called resonium.
• People who have Addison's disease (a condition affecting the adrenal glands).
• People who have had gastric bypass surgery.
• People already taking part in another interventional clinical trial.
• People with lactose intolerance.
• People whose blood potassium level is above 4.9 mmol/l at screening.

Important: Always verify eligibility with the trial site directly before applying.